Title 1

Cytogenetic & Molecular analysis in Premature Ovarian Failure 2

- Chetan sahni¹, Rima dada² 3
- 1. Institute of Medical Sciences, Banaras Hindu University, Varanasi, India 4
- All India Institute of Medical Sciences, New Delhi, India 5 2.
- First Author: Dr. CHETAN SAHNI, Assistant Professor, IMS-BHU, chetansahni@bhu.ac.in 6
- Corresponding 7 Dr. Rima Dada, Professor, **AIIMS** NEW DELHI, Author:
- rima dada@rediffmail.com 8

ABSTRACT:

9

10

24

29

32

33

- **Introduction:** Premature Ovarian Failure (POF) being a heterogeneous genetic disease involves the 11
- 12 interaction of multiple genetic defects and environmental factors and has been associated with
- 13 several chromosomal abnormalities, single gene mutations, and genetic polymorphisms. BMP15 is a
- member of the transforming growth factor β (TGF-β) family. BMP15 gene product (protein) have 3 14
- domians, mature domain (c-terminal region) of BMP15 binds to receptors located on granulosa cell 15
- surface to participate in key steps regarding ovarian function, such as granulosa cell proliferation 16
- 17 and follicle maturation, ovulation rate modulation, oocyte competence determination and regulating
- granulosa cell sensitivity to FSH. Single nucleotide polymorphisms (SNPs) of the BMP-15 gene are 18
- associated with POF. 19
- Materials & Methods: 30 POF patients and 30 healthy age matched controls were recruited for 20
- cytogenetic and molecular analysis. 10 ml whole blood was collected for karyotyping and PCR and 21
- 22 PCR was performed for known SNPs of BMP-15 gene (-9C>G, 538G>A, 788insTCT and 852C>T)
- respectively. Amplified PCR products were sequenced commercially. 23
- **Observation/Result:** Thirty cases (mean age 30 years) and thirty healthy controls (mean age 23 25
- years) were recruited for the study. On cytogenetic analysis 2 cases had a 45, XO chromosomal 26
- complement. One case was heterozygous for the SNP (-9C>G) and one control was homozygous for 27
- the same SNP. 28
- **Discussion:** The prevalence of this SNP was about 10.7% in cases & 3.3% in healthy controls. This 30
- polymorphism in promoter region may cause altered expression of the gene and results in POF. 31

INTRODUCTION

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Premature ovarian failure (POF) refers to the development of amenorrhea due to cessation of ovarian function before the age of 40 years and is characterized by low estrogen and elevated serum gonadotropin. Elevated levels of Follicle Stimulating hormone (FSH) (≥40 mIU/ml) detected on at least two occasions a few weeks apart, is indicative of premature ovarian failure.^{1,2} The triad for the diagnosis of POF is amenorrhea, hypergonadotropism, and hypoestrogenism. POF affects approximately 1% of the female population by age of 40 years and 0.1% by age of 30 years worldwide.³ POF is not the same as natural menopause, as natural menopause is an irreversible condition, while POF is characterized by intermittent ovarian function in one half of young women.⁴

In the patients of POF, Hypoestrogenism can be satisfactorily treated by hormone replacement therapy. In contrast, fertility cannot be recovered when the diagnosis of POF (or end-stage POI- premature ovarian insufficiency) is generally reached and is often compromised in the early phases of the disease when the clinical manifestations are absent.⁵ The age of onset varies widely, depending on the age of onset, the disorder can manifest as primary amenorrhea, without menarche, or secondary amenorrhea after the pubertal development.⁶

Kinch et al., (1965) found that there are two histopathological types of POF, afollicular, and follicular form. In the afollicular form, there is a total depletion of ovarian follicles with permanent loss of ovarian function. In the follicular form, follicular structures are still preserved, hence a possibility of either spontaneous or induced return of ovarian function exists.

Causes of Ovarian Failure

The causes of premature ovarian failure broadly categorized into the genetic and pathological

category. Amongst the genetic causes numerical & structural anomalies of the X chromosome

adversely affect ovarian function. The most common form of X chromosome defect is Turner's

60 syndrome. Besides genetic causes, a wide spectrum of pathogenic mechanisms like autoimmune,

61 metabolic (galactosemia), infections (mumps), iatrogenic (anti-cancer treatment) may lead to the

62 development of POF. But, the Genetic causes of POF probably comprise about one-third to one-half

63 of all cases.8

57

58

59

64 **Genetic Causes**

65 Chromosomal defects involving the X-chromosome are frequently seen in women with POF. The

66 deletion of X chromosome makes follicle or ovum unstable. In the majority of cases, X

67 chromosome defects cause deletion or disruption of genes located in the critical region of the X

chromosome between Xq13 and Xq26, which are critical for ovarian function. Several genes

responsible for oogenesis and normal ovarian functions are present on the X chromosome and

70 autosomes.

68

69

71 Genes Involved

72 Many genes on the X chromosome and autosomes regulate ovarian function. In a meta-analysis, D.

73 Pu et.al reported that five genes BMP15, ESR1, FMR1, FSHR, and INH are very important for

74 normal ovarian functions. They also found that single nucleotide polymorphisms and mutations in

75 these genes were found to be significantly more common in patients with POF compared with

76 controls.9

77

BMP 15 Gene

In our study, we had evaluated the polymorphism in the *BMP15* gene, as the *BMP15* gene has a very important role in ovarian functions. The *BMP15* is a member of the transforming growth factor β (TGF-β) family, which is expressed by oocytes from the early stages of follicular maturation and during all stages of development.10 BMP15 protein can form homodimers (BMP15: BMP15) or heterodimers (BMP15: GDF9). The secreted soluble dimer binds to receptors located on the granulosa cell surface to participate in key steps regarding ovarian function, such as granulosa cell proliferation and follicle maturation, ovulation rate modulation, oocyte competence determination and regulating granulosa cell sensitivity to FSH.¹¹

In the Sanger sequencing projects of the *BMP15* encoding region in panels of POF patients, more than 15 missense variants were identified.¹² Most of them were located in the protein pro-region. This scenario led to engage the researchers in a recent functional exploration of whether *BMP15* promoter polymorphism might be related to the POF phenotype. It has been also established that this variant modifies the paired-like homeodomain transcription factor 1 (PITX1) binding site and leads to *BMP15* promoter transactivation disturbances.¹³ This might suggest that fine-tuning of *BMP15* expression is critical for normal human ovarian physiology.

BMP15 gene located on the short arm of the X chromosome (Xp11.2) within a 'POF critical region'. ¹⁴ BMP15 gene has two exons of 328 bp and 851 bp. In humans, mutations in the BMP15 gene have been found in association with both primary amenorrhea and secondary amenorrhea in several worldwide POF cohorts with a variable prevalence between 1.5 and 12%. ⁵

In light of these findings, one could hypothesize that *BMP15* variations might play a predisposing role in POF. The functional mechanism by which *BMP15* variants with a proven biological impact may disturb ovarian folliculogenesis is presently unknown. It may be predicted that a diminished *BMP15* paracrine signal in the follicle would involve an impairment of the anti-apoptotic effects on granulosa cells.⁵ Indeed, further studies are needed to understand the exact role of *BMP15* variants in POF pathogenesis. Thus in our study, we have evaluated the cytogenetic and molecular basis (mutation in *BMP15*) of disease in cases of premature ovarian failure.

Materials and Methods

The study population consisted of 30 females of POF with no identifiable etiology after detailed clinical, gynecological evaluation. The control group included 30 healthy females with normal menstrual and fertility history. The relevant information regarding physical examination, clinical investigations, developmental milestones, occupational or environmental exposure to heat, radiation, chemicals, or toxins, were documented in a pre-designed proforma. Written informed consent was taken from each patient and control. The study was approved by the Institute Ethical Committee-A.I.I.M.S. New Delhi (ref-no. IESC/T-150/01.04.2015).

The Inclusion criteria for study (infertile) group were: only Cases of idiopathic POF with primary and secondary amenorrhea after detailed gynecological & cytogenetic investigations, with no recent history of illness, fever or medication (in past three months).

The Inclusion criteria for Controls (fertile) group were: Controls who had normal menstrual and fertility history, with no recent history of illness, fever, or medication (in the past three months).

The Exclusion criteria for the study group and control group: 1) Gross dysmorphic 130 abnormalities, structural defects, and systemic infection of the urogenital/reproductive system. 2) 131 History of surgical intervention or trauma of genital/reproductive tract obstruction. 3) History of 132 miscarriage, abortion whether spontaneous or induced. 4) Syndromic cases as Turner and Klinefelter 133 (on cytogenetic evaluation). 134

For this case-control study, 30 cases of mean age 23 ± 4.15 years were recruited from the Department of Obstetrics & Gynecology, AIIMS, New Delhi, and 30 controls of mean age 25 ± 3.49 years were recruited from a group of healthy wives of cases with male factor infertility & healthy female volunteers from AIIMS, New Delhi. Cases included in this study were presented with premature ovarian failure but on clinical examination, no obvious cause was determined in them and all cases were phenotypically normal. So these cases were found idiopathic and further cytogenetic (karyotyping) and molecular (PCR) analyses were needed in all these cases, While Controls were presented with normal menstrual and fertility history, so cytogenetic (karyotyping) analysis was not done in controls. Three genetic analyses were used to observe the result.

- 1. Cytogenetic (Karyotyping) analysis in Cases (infertile group)
- 2. Molecular (PCR) analysis in both Cases (infertile group) & Controls (healthy fertile group) 147

1. Cytogenetic analysis

126

127

128

129

135

136

137

138

139

140

141

142

143

144

145

146

148

149

In all infertile cases, the chromosomal analysis was done to identify any numerical or structural chromosomal aberration. The metaphases were captured under 100X (Olympus optical company, Ltd., Tokyo, Japan). The captured metaphases were analyzed using image analysis software Cytovision 3.7 provided by Applied Imaging (ZEISS microscope, Germany) and classified according to ISCN 2005. At least 50 metaphases were analyzed and karyotyped for each individual.

In karyotyping, it was observed that two cases out of 30 presented with Turner's karyotype (45, X0). Although, in these two cases Turner's karyotype (45, X0) was observed but they were phenotypically normal. (fig. 1) These two cases were excluded from the study as cytogenetically normal, idiopathic cases were included in this study. The remaining 28 cases were cytogenetically normal.

2. Molecular (PCR) analysis

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

SNPs of the BMP15 gene were observed by using molecular (PCR) analysis. This molecular analysis was done in 28 cases which were found clinically as well as cytogenetically normal but have the phenotype of premature ovarian failure and in 30 healthy fertile controls. Total Genomic DNA was extracted from peripheral blood. Blood samples were collected from cases and controls in EDTA vials only after informed consent. DNA was isolated from 58 (28 cases and 30 controls) samples. Genomic DNA was isolated from peripheral blood samples by miller's protocol of DNA isolation. DNA was quantified by using a Nanodrop spectrophotometer (Thermo Scientific Corp., USA).

Analysis of nucleotide variations in the BMP15 gene

The nucleotide variations in the BMP15 gene were analyzed in cases (n=28) and controls (n=30). In 177 the analysis of the BMP15 gene, 2 exons (with reference to July 2009 assembly of ensemble. 178 179 Amplicons (amplified exons) were electrophoresed using 1.8 % agarose gel. Amplified PCR 180 products were purified using gel/PCR DNA fragments extraction kit (Geneaid Biotech Ltd., Sijhih 181 City Taiwan. Cat no DF100). Purified PCR products were sent for sequencing at MCLAB 182 (Molecular Laboratories) South 94080. 183 Cloning San Francisco. CA U.S.A. 184 (http://www.mclab.com/product.php?productid=19071). DNA sequences were analyzed against BMP15 reference sequence ENST00000252677.3 using ClustalW2 (multiple sequence alignment 185 program for DNA available at http://www.ebi.ac.uk/Tools/clustalw2/index.html provided by 186 European Molecular Biology Laboratory (EMBL) – European Bioinformatics Institute (EBI). 187 188 189 190 Statistical Analysis 191 The data has been expressed as mean ± SD and/or median (minimum, maximum) as per the 192 193 statistical conventions. Associations were investigated by the chi-square test or fisher's exact test. SPSS 11.5 (Texas, USA) was used for statistical analysis. Univariate and multivariable logistic 194 regression was done to see the unadjusted and adjusted odds ratio with 95% CI. All the p-values less 195 196 than 0.05 were taken as significant. 197 198 199 200

RESULTS

MOLECULAR ANALYSIS

202

By using sequencing analysis software (Chromas pro-2.4), it was observed that, in 3 cases, 203 polymorphism at rs3810682: g.50910775C>G Promoter region of exon -1 of the BMP15 gene was 204 present. Of the 3 in one case, it was homozygous change while in 2 cases, the heterozygous change 205 206 was observed. (fig.2) 207 Out of 3 in one case, it was homozygous change. The frequency of the homozygous allele SNPs in 208 cases was 3.7%. In other 2 cases, the heterozygous change was observed. The frequency of the 209 210 heterozygous allele SNPs in cases was 7%. Besides cases, in one control heterozygous polymorphism was also observed. The frequency of heterozygous allele SNPs in control was 3.3% 211 and frequency of the homozygous allele SNPs in control was 0%. (Table no. 2) All these changes 212 213 were present at the same location (Promoter region of exon -1 of the *BMP15* gene). 214 215 216 Fisher's exact test was used to analyze the frequency of SNP variant. It has been found the 217 prevalence of BMP-15 SNP (rs3810682: g.50910775C>G) among cases was 10.7% and in controls 3.3 %. Although, P-value observed 0.344 (at 95% significance level), which was not significant but 218 prevalence was more in cases as compared to controls. (Table no. 3) 219 220 **Discussion** 221 The possible involvement of BMP15 in POF pathogenesis was supported by evidence in animal 222 models.¹⁵ Di pasquale et.al, 2004 reported the first mutation of the *BMP15* gene in two sisters with 223 ovarian dysgenesis. They also described the significant association of heterozygous BMP15 gene 224 variants with the POF phenotype in humans (seven of 166 patients: 4.2%; P- 0.003 vs. controls). 225 These findings are consistent with the critical role played by BMP15 in human folliculogenesis. ¹⁶ 226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

Fonesca et al., 2014, were taken an in-silico approach, which identified that the PITX1 (pituitary homeobox 1 protein) factor binds to a sequence located between -14 to -8 of the BMP15 promoter. It was shown that PITX1 and BMP15 are co-expressed in both human adult oocytes and in adult mouse ovaries. Functional in-vitro experiments showed that both BMP15 promoter constructs (BMP15- prom-G and BMP15-prom-C) were activated by PITX1. A statistically significant 1.6 fold increase in BMP15 transcription activity conferred by the BMP15-prom-G construct was found. This feature might lead to alterations in granulosa cell proliferation rate, which may contribute towards POF molecular etiology.¹³ In the present study, we, therefore, decided to verify the prevalence of BMP15 gene alterations among the POF populations. It was observed that both heterozygous and homozygous SNPs (BMP15 GENE Promoter region: -9C>G rs3810682: g.50910775C>G) distribution in cases and controls) were present in 3 cases among 28 cases and in one control was observed. The prevalence was higher in cases as compared to controls. By using fisher exact t-test, we observed that although prevalence was higher in cases but p-value was 0.34, which was not significant at 95% CI. This might be due to small sample size. In present study also observed that heterozygous SNPs were more than Homozygous SNPs. Out of 3 in one case, it was homozygous change. The frequency of homozygous allele SNPs in cases was 3.7%. In other 2 cases, the heterozygous change was observed. The frequency of heterozygous allele SNPs in cases was 7%. Besides cases, in one control heterozygous polymorphism was also observed. The frequency of heterozygous allele SNPs in control was 3.3% and frequency of homozygous allele SNPs in control was 0%. All these changes were present at the same location (Promoter region of exon -1 of the BMP15 gene). Two cases

presented with secondary amenorrhea and one with primary amenorrhea. So it suggesting that SNPs associated with BMP-15 gene cause both primary and secondary amenorrhea.

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275


CONCLUSION

In previous literature, it has been observed that there is a strong correlation between mutation or SNPs of BMP-15 gene and premature ovarian failure as the BMP-15 gene is a regulator of important actions of granulosa cells of the ovary.

In the present study, it was observed that both heterozygous and homozygous SNPs were present in 3 of 28 cases and in one control heterozygous SNPs was observed. The prevalence was higher in cases as compared to controls. By using fisher exact t-test, we observed that although prevalence was higher in cases but p-value was 0.34, which was not significant at 95% CI. This insignificance was due to recruitment of few cases, who presented with idiopathic POF which have normal (46, XX) karyotype. In present study also observed that heterozygous SNPs were more than Homozygous SNPs. Two cases presented with secondary amenorrhea and one with primary

amenorrhea. So it suggesting that SNPs associated with BMP-15 gene cause both primary and secondary amenorrhea

Further study, needed with a large cohort of idiopathic cases of premature ovarian failure, to determine the prevalence of allele frequency observed during the study and its genotypephenotype correlation among both the primary & secondary ovarian failure patients in Indian



301 7. Kinch R, Plunkett E, Smout M, Carr D. Primary Ovarian Failure; A Clinicopathological 302 And Cytogenetic Study. Am J Obstet Gynecol. 1965 Mar 1; 91:630-44. 303 304 8. Kumar M, Pathak D, Venkatesh S, Kriplani A, Ammini AC, Dada R. Chromosomal 305 abnormalities & oxidative stress in women with premature ovarian failure (POF). The Indian 306 307 Journal of Medical Research. 2012; 135(1):92-97. 308 9. Pu D, Xing Y, Gao Y, Gu L, Wu J. Gene variation and premature ovarian failure: a meta-309 310 analysis. Eur J Obstet Gynecol Reprod Biol. 2014 Nov; 182:226-37 311 10. Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM. The bone morphogenetic 312 protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol. 1998 Dec; 12(12):1809-17. 313 314 315 11. Hanrahan JP, Gregan SM, Mulsant P, Mullen M, Davis GH, Powell R, Galloway SM. Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with 316 both increased ovulation rate and sterility in Cambridge and Belclare sheep (Ovis aries). Biol 317 Reprod. 2004 Apr; 70(4):900-9 318 319 Persani L, R. Rossetti, E. Di Pasquale, C. Cacciatore, S. Fabre The fundamental role of 320 12. bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders. 321 322 Hum. Reprod. Update, 20 (2014), pp. 869–883 323 Fonseca DJ, Ortega-Recalde O, Esteban-Perez C, Moreno-Ortiz H, Patiño LC, Bermúdez 13. 324

OM, Ortiz AM, Restrepo CM, Lucena E, Laissue P. BMP15 c.-9C>G promoter sequence variant

- 326 may contribute to the cause of non-syndromic premature ovarian failure. Reprod Biomed Online.
- 327 2014 Nov; 29(5):627-33.

328

332

337

341

- 14. Zinn AR, Tonk VS, Chen Z, Flejter WL, Gardner HA, Guerra R, Kushner H, Schwartz S, 329
- Sybert VP, Van Dyke DL, Ross JL. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1. 330
- Am J Hum Genet. 1998 Dec; 63(6):1757-66. 331
- Galloway SM, McNatty KP, Cambridge LM, Laitinen MP, Juengel JL, Jokiranta TS, 333 15.
- McLaren RJ, Luiro K, Dodds KG, Montgomery GW, Beattie AE, Davis GH, Ritvos O. Mutations 334
- in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a 335
- 336 dosage-sensitive manner. Nat Genet. 2000 Jul; 25(3):279-83.
- 16. Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic Ovarian Failure Associated 338
- with an Inherited Mutation of Human Bone Morphogenetic Protein-15 (BMP15) Gene. American 339
- 340 Journal of Human Genetics. 2004; 75(1):106-111.
- McNatty KP, Galloway SM, Wilson T, Smith P, Hudson NL, O'Connell A, Bibby AH, Heath 17. 342
- DA, Davis GH, Hanrahan JP, Juengel JL. Physiological effects of major genes affecting ovulation 343
- rate in sheep. Genet Sel Evol. 2005; 37 Suppl 1:S25-38. 344






Fig. 2: Chromatogram showing sequencing results

Designed primers: for 2 exons of BMP15 gene.						
Exon 1	Forward-GGA GCC AGG ATG CAG TTA TCT GC					
	Reverse -CAG GGC AGT ATG GGG GCA TAA C					
Exon 2	Forward-GGT TCT GGA ATA ACA AGG GAC					
	Reverse-CTC TCC TCC AGT TTC CTG G					

Table no. 1: Primers for Exon-1 & Exon-2 of BMP15 gene

	CASES		CONTROL		TOTAL	
Allele	N	%	N	%	N	%
Heterozygous	2	7%	1	3.3%	3	5.2%
(C/G)						
Homozygous	1	3.7%	0	0%	1	1.7%
(G/G)						
Homozygous	25	89.3%	29	96.3%	54	93.1%
(Reference-Normal)						
(C/C)						
Total	28	%	30	100%	58	100%

Table no. 2: Allele frequency of SNPs among Cases & Controls

Group	BMP15 reference gene	BMP15 reference gene BMP15 variant (CG/GG)HOMO/	
	(CC-Wild type)	HETEROZYGOUS VARIANT	
Cases	25(89.3%)	3(10.7%)	28 (100%)
Controls	29(96.7%)	1(3.3%)	30 (100%)
Total	54(93.1%)	4(6.9%)	58(100%)

Table no. 3: BMP15 GENE (Rs3810682: g.50910775C>G) SNPs distribution in cases and controls